Profile | GDS2987 / GI_36054106-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 442.7 | 90 |
GSM215244 | HMVEC_vehicle_rep2 | 483.1 | 90 |
GSM215253 | HMVEC_vehicle_rep3 | 445.2 | 90 |
GSM215254 | HMVEC_atorvastatin_rep1 | 1964.7 | 97 |
GSM215282 | HMVEC_atorvastatin_rep3 | 2012.7 | 97 |
GSM215344 | HMVEC_atorvastatin_rep2 | 2019.4 | 97 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 698 | 92 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 611.5 | 91 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 669.7 | 92 |
GSM215294 | HMVEC_SLx2119_rep1 | 348.7 | 88 |
GSM215295 | HMVEC_SLx2119_rep2 | 319.4 | 86 |
GSM215296 | HMVEC_SLx2119_rep3 | 379.3 | 88 |
GSM215297 | PASMC_vehicle_rep1 | 50.6 | 59 |
GSM215298 | PASMC_vehicle_rep2 | 156.2 | 78 |
GSM215310 | PASMC_vehicle_rep3 | 31.6 | 45 |
GSM215311 | PASMC_atorvastatin_rep1 | 738.5 | 92 |
GSM215312 | PASMC_atorvastatin_rep2 | 824.5 | 93 |
GSM215313 | PASMC_atorvastatin_rep3 | 848 | 92 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 90.6 | 73 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 58.4 | 67 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 44.7 | 59 |
GSM215327 | PASMC_SLx2119_rep1 | 43.8 | 59 |
GSM215328 | PASMC_SLx2119_rep2 | 16 | 29 |
GSM215329 | PASMC_SLx2119_rep3 | 51.8 | 65 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 0.6 | 2 |
GSM215332 | Fibroblasts_vehicle_rep3 | 4.2 | 15 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 0.7 | 2 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 3.1 | 9 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | 5.4 | 16 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 2.1 | 5 |